Evidence map›Paper›PMID 38715773›Full record

ArticleFrontiers in oncology2024

The functional role of Nudt2 in human triple negative breast cancer.

Rasha Abu-Rahmah, Hovav Nechushtan, Sanaa Hidmi, Amichay Meirovitz, Ehud Razin, Tamar Peretz

Abstract read
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rasha Abu-RahmahDepartment of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Hovav NechushtanDepartment of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Sanaa HidmiDepartment of Biochemistry and Molecular Biology, Institute for Medical Research Israel-Canada, the Hebrew University of Jerusalem, Jerusalem, Israel.
Amichay MeirovitzDepartment of Oncology, Soroka-Ben Gurion University Medical Center, Beer-Sheeva, Israel.
Ehud RazinDepartment of Biochemistry and Molecular Biology, Institute for Medical Research Israel-Canada, the Hebrew University of Jerusalem, Jerusalem, Israel.
Tamar PeretzDepartment of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The main known function of Nudix hydrolase 2 (Nudt2) is to hydrolyze the secondary messenger diadenosine 5', 5'''-p1, p4-tetraphosphate (Ap4A). In this study we examined the role of Nudt2 in breast carcinoma through its expression in human invasive ductal carcinoma tissues, and its functions in human triple negative breast cancer (TNBC) cell lines. A significantly higher expression of Nudt2 was observed in human invasive ductal carcinoma tissues compared to that in normal breast tissue. Knockdown of Nudt2 in TNBC cell lines resulted in a significant reduction in cellular proliferation via the Ki67 marker, accompanied by G0/G1 phase cell cycle arrest, in the migration and invasion of these cells and in tumorigenicity and anchorage-independent growth. It can therefore be concluded that Nudt2 plays a significant role in promoting TNBC growth.

Indexed as

Anchorage-independent growthinvasionmigrationNUDT2triple negative breast cancer (TNBC)

Identifiers

PMID38715773
PMCPMC11075069

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.